TOKYO, May 26 (Pulse News Wire) – Abc CO.,LTD. (8783.T) announced today that its board of directors approved the sale of all shares held in related company Lumirise.
Following the transaction, which is set to take place on May 28, 2026, Lumirise will be excluded from the group. Lumirise, founded on November 24, 2021, specializes in developing regenerative medical treatments using de-differentiated fat cells for humans and animals. The decision to sell the shares was made due to Lumirise's recent poor performance, with ongoing operating losses and risks associated with future operations. Abc CO.,LTD.
Believes focusing resources on its core businesses—financial services and Web3-related ventures—is more strategic amid changing market conditions. Key details of the transaction include: - Total number of shares being sold: 2,498 (voting rights ratio: 35.99%) - Number of shares acquired previously: 2,498 (voting rights ratio: 35.99%) - Post-sale shareholding: 0 (voting rights ratio: 0%) The agreement also includes a careful evaluation of Lumirise’s recent financial status and potential future risks, leading to a consensus on the final price. The company expects the deal to strengthen its revenue base and reduce long-term uncertainties. Abc CO.,LTD.
Will continue to monitor the impact of this divestiture on its consolidated earnings and will disclose any significant developments promptly.
🔴 Confidence: Review recommended AI-translated content.